{
    "nct_id": "NCT05528510",
    "official_title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis",
    "inclusion_criteria": "* Signed informed consent form\n* 18 years of age or older\n* Documented diagnosis of ulcerative colitis (UC) at least 12 weeks prior to screening\n* Moderately to severely active UC as per the modified Mayo score\n* Demonstrated inadequate response to or intolerance of conventional therapy and/or advanced therapy as defined in the protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease\n* Surgery within 8 weeks before screening or planned surgery during the study that may confound the evaluation of benefit from study intervention\n* Receiving prohibited medications and treatments\n* UC limited to the rectum only\n* Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) corona virus disease (COVID-19) infection",
    "miscellaneous_criteria": ""
}